Familiar targets with a twist
First-in-human study initiations feature variations on well-trodden targets, plus a minor hiccup for OncoC4.
CD47’s long goodbye
Despite magrolimab’s latest flop, efforts to target CD47 continue.
New phase 1 projects enter hot fields
Analysis of industry assets newly into human trials reveals three Car-T therapies and some familiar targets.
Akeso builds on earlier success with bispecifics
Buoyed by the success of cadonilimab and ivonescimab the Chinese group takes two more bispecific MAbs into human trials.
Interview – Coherus sees the stars aligning at last
After two years Loqtorzi is on the US market at last, and Coherus looks to its Surface acquisition to play the combo game.
First phase 1 starters challenge Pluvicto and Revolution
The latest first-in-human trial entrants include several novel mechanisms, a PSMA radioconjugate and a new pan-KRAS challenger.
